{"id":4000082624,"date":"2026-07-15T11:36:40","date_gmt":"2026-07-15T09:36:40","guid":{"rendered":"https:\/\/new.igihe.com\/french\/?p=4000082624"},"modified":"2026-07-15T14:24:45","modified_gmt":"2026-07-15T12:24:45","slug":"rdc-loms-teste-un-nouveau-medicament-contre-ebola","status":"publish","type":"post","link":"https:\/\/new.igihe.com\/french\/rdc-loms-teste-un-nouveau-medicament-contre-ebola\/","title":{"rendered":"RDC : l\u2019OMS teste un nouveau m\u00e9dicament contre Ebola"},"content":{"rendered":"\n

Baptis\u00e9e ‘EBO-PEP’, cette \u00e9tude vise \u00e0 d\u00e9terminer si l\u2019obeldesivir, un m\u00e9dicament antiviral d\u00e9velopp\u00e9 par la soci\u00e9t\u00e9 am\u00e9ricaine Gilead Sciences, peut emp\u00eacher les personnes ayant \u00e9t\u00e9 en contact avec des malades confirm\u00e9s d\u2019Ebola de d\u00e9velopper la maladie. Le traitement est administr\u00e9 par voie orale.<\/p>\n\n\n\n

L\u2019essai est men\u00e9 dans la province de l\u2019Ituri, principal foyer de l\u2019\u00e9pid\u00e9mie, en collaboration avec les autorit\u00e9s sanitaires congolaises et plusieurs partenaires internationaux. Il concerne environ 1 000 personnes \u00e2g\u00e9es de 12 ans et plus, ayant \u00e9t\u00e9 expos\u00e9es \u00e0 un cas confirm\u00e9 dans les cinq jours pr\u00e9c\u00e9dant leur inclusion, mais ne pr\u00e9sentant pas encore de sympt\u00f4mes.<\/p>\n\n\n\n

Les participants seront suivis quotidiennement pendant 21 jours, avec une \u00e9valuation finale pr\u00e9vue apr\u00e8s 42 jours, afin d\u2019observer si le m\u00e9dicament r\u00e9duit le risque d\u2019infection ou de d\u00e9veloppement de la maladie.<\/p>\n\n\n\n

Selon l\u2019OMS, l\u2019obeldesivir a montr\u00e9 des r\u00e9sultats encourageants lors d\u2019\u00e9tudes pr\u00e9cliniques, notamment contre certains virus appartenant \u00e0 la famille des filovirus, qui comprend le virus Ebola. L\u2019organisation esp\u00e8re que cet essai permettra d\u2019identifier un outil suppl\u00e9mentaire pour prot\u00e9ger les personnes fortement expos\u00e9es.<\/p>\n\n\n\n

\u00ab Chaque grande avanc\u00e9e commence par un espoir \u00bb, a notamment indiqu\u00e9 le directeur g\u00e9n\u00e9ral de l\u2019OMS, Dr Tedros Adhanom Ghebreyesus, soulignant \u00e9galement que cette recherche pourrait repr\u00e9senter une \u00e9tape importante dans la pr\u00e9vention des infections.<\/p>\n\n\n\n

\u00c0 ce jour, il n\u2019existe aucun vaccin ni traitement sp\u00e9cifiquement homologu\u00e9 contre Ebola de type Bundibugyo, contrairement \u00e0 d\u2019autres souches du virus Ebola pour lesquelles des solutions m\u00e9dicales ont d\u00e9j\u00e0 \u00e9t\u00e9 d\u00e9velopp\u00e9es.<\/p>\n\n\n\n

L\u2019\u00e9pid\u00e9mie actuelle, officiellement d\u00e9clar\u00e9e le 15 mai 2026 apr\u00e8s l\u2019apparition de plusieurs cas dans la province de l\u2019Ituri, s\u2019est ensuite \u00e9tendue \u00e0 d\u2019autres zones de la RDC ainsi qu\u2019\u00e0 l\u2019Ouganda.<\/p>\n\n\n\n

Selon les derni\u00e8res donn\u00e9es disponibles, la RDC a d\u00e9pass\u00e9 le seuil de 2.000 confirm\u00e9s pour atteindre 2.011 cas, dont 754 d\u00e9c\u00e8s li\u00e9s \u00e0 cette flamb\u00e9e \u00e9pid\u00e9mique.<\/p>\n\n\n\n

L\u2019OMS estime toutefois que l\u2019ampleur r\u00e9elle de la crise pourrait \u00eatre plus importante que les chiffres officiels, en raison notamment des difficult\u00e9s de surveillance dans certaines zones touch\u00e9es. Des experts avancent que le nombre r\u00e9el de cas pourrait \u00eatre deux \u00e0 quatre fois sup\u00e9rieur aux donn\u00e9es actuellement rapport\u00e9es.<\/p>\n\n\n\n

Face \u00e0 cette situation, les autorit\u00e9s sanitaires congolaises, l\u2019OMS et leurs partenaires intensifient les efforts de surveillance, de prise en charge des patients et de recherche m\u00e9dicale afin de mieux contr\u00f4ler cette \u00e9pid\u00e9mie.<\/p>\n\n\n\n

\"\"
L\u2019essai est men\u00e9 dans la province de l\u2019Ituri, principal foyer de l\u2019\u00e9pid\u00e9mie, en collaboration avec les autorit\u00e9s sanitaires congolaises et plusieurs partenaires internationaux<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"

L\u2019Organisation mondiale de la Sant\u00e9 (OMS) a lanc\u00e9 un nouvel essai clinique en R\u00e9publique d\u00e9mocratique du Congo (RDC) pour \u00e9valuer l\u2019efficacit\u00e9 d\u2019un antiviral destin\u00e9 \u00e0 pr\u00e9venir l\u2019infection chez les personnes expos\u00e9es au virus Ebola de type Bundibugyo, alors que l\u2019\u00e9pid\u00e9mie continue de progresser dans l\u2019est du pays.<\/p>\n","protected":false},"author":452,"featured_media":4000082625,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7529,7546],"tags":[7618],"byline":[7717],"hashtag":[],"class_list":["post-4000082624","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite-3","category-sante-20","tag-grandlacnews","byline-igihe"],"bylines":[{"id":7717,"name":"IGIHE","slug":"igihe","description":"","image":{"id":0,"url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&f=y&r=g","alt":"Default avatar","title":"Default avatar","caption":"","mime_type":"image\/jpeg","sizes":[]},"user_id":393}],"contributors":[{"id":7717,"name":"IGIHE","slug":"igihe","description":"","image":{"id":0,"url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&f=y&r=g","alt":"Default avatar","title":"Default avatar","caption":"","mime_type":"image\/jpeg","sizes":[]},"user_id":393}],"featured_image":{"id":4000082625,"url":"https:\/\/cdn.igihe.com\/fr\/2026\/07\/VIREBLLLL.jpg","alt":"","caption":"","mime_type":"image\/jpeg","width":1200,"height":675,"sizes":{"thumbnail":{"url":"https:\/\/cdn.igihe.com\/fr\/2026\/07\/VIREBLLLL.jpg","width":1200,"height":675},"medium":{"url":"https:\/\/cdn.igihe.com\/fr\/2026\/07\/VIREBLLLL.jpg","width":1200,"height":675},"medium_large":{"url":"https:\/\/cdn.igihe.com\/fr\/2026\/07\/VIREBLLLL.jpg","width":1200,"height":675},"large":{"url":"https:\/\/cdn.igihe.com\/fr\/2026\/07\/VIREBLLLL.jpg","width":1200,"height":675},"full":{"url":"https:\/\/cdn.igihe.com\/fr\/2026\/07\/VIREBLLLL.jpg","width":1200,"height":675}}},"_links":{"self":[{"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/posts\/4000082624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/users\/452"}],"replies":[{"embeddable":true,"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/comments?post=4000082624"}],"version-history":[{"count":3,"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/posts\/4000082624\/revisions"}],"predecessor-version":[{"id":4000082680,"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/posts\/4000082624\/revisions\/4000082680"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/media\/4000082625"}],"wp:attachment":[{"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/media?parent=4000082624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/categories?post=4000082624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/tags?post=4000082624"},{"taxonomy":"byline","embeddable":true,"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/byline?post=4000082624"},{"taxonomy":"hashtag","embeddable":true,"href":"https:\/\/new.igihe.com\/french\/wp-json\/wp\/v2\/hashtag?post=4000082624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}